This activity is intended for medical oncologists, hematology-oncology fellows, hematologists and other healthcare providers involved in the treatment of non-Hodgkin’s lymphomas (NHL).
OVERVIEW OF ACTIVITY
Hematologic cancer includes the lymphomas, the leukemias, multiple myeloma and other related disorders such as myelodysplastic syndromes and myeloproliferative diseases, all stemming from lymphoid and myeloid progenitor cell lines. Taken together it is estimated that approximately 139,860 new lymphoid and myeloid cancer cases were identified in the United States in 2009 with 53,240 individuals dying from these diseases in the same year. Cytotoxic chemotherapies, autologous and/or allogeneic hematopoietic stem cell transplant and biologic or molecular-targeted therapies have been the focus of treatment algorithms designed to assist clinicians in the clinical care of patients with hematologic cancer. Despite the existence of such tools, many areas of controversy persist within the academic and community settings, especially within the area of NHL. The recent entry of novel agents and the emergence of extensive practice-changing clinical trial data have created clinical scenarios in which multiple treatment options may be available but the optimal strategy is highly debatable. To bridge the gap between research and patient care, this CME activity will use the perspectives of clinical investigators on key management challenges and controversies in NHL to assist medical oncologists, hematologist-oncologists, hematology-oncology fellows and other cancer clinicians in the formulation of up-to-date and appropriate treatment strategies.
- Compare and contrast clinical investigator use of midtreatment PET scans to evaluate response to therapy, and consider whether results of these tests should influence the decision to alter therapy selection.
- Evaluate the incorporation of lenalidomide by clinical investigators in the nonprotocol care of their patients with DLBCL.
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Research To Practice designates this web activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
HOW TO USE THIS CME ACTIVITY
This CME activity consists of a text component. To receive credit, the participant should review the treatment preference matrix and complete the Post-test and Educational Assessment and Credit Form located on our website at http://www.researchtopractice.com/COCNHL11/1/CME.
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:
James O Armitage, MD
The Joe Shapiro Professor of Medicine
Division of Oncology/Hematology
Department of Internal Medicine
University of Nebraska Medical Center
Advisory Committee: Eisai Inc, Seattle Genetics, ZIOPHARM Oncology Inc; Data Monitoring Committee: GlaxoSmithKline.
Bruce D Cheson, MD
Professor of Medicine
Head of Hematology
Director of Hematology Research
Georgetown University Hospital
Lombardi Comprehensive Cancer Center
Advisory Committee: Allos Therapeutics, Celgene Corporation, Cephalon Inc, GlaxoSmithKline, Millennium — The Takeda Oncology Company; Consulting Agreement: Millennium — The Takeda Oncology Company.
Bertrand Coiffier, MD, PhD
Professor of Hematology
Head, Department of Hematology
Hospices Civils de Lyon and Université Claude Bernard
Advisory Committee and Paid Research: Amgen Inc, Bristol-Myers Squibb Company, Calistoga Pharmaceuticals Inc, Celgene Corporation, Johnson & Johnson Pharmaceuticals, MedImmune Inc, Merck and Company Inc, Merck Sharp & Dohme Corp, Millennium — The Takeda Oncology Company, Pfizer Inc, Pharmacyclics Inc, Roche Laboratories Inc, Sandoz, Sanofi, Servier; Speakers Bureau: Amgen Inc, Calistoga Pharmaceuticals Inc, Celgene Corporation, Johnson & Johnson Pharmaceuticals, MedImmune Inc, Merck and Company Inc, Merck Sharp & Dohme Corp, Pharmacyclics Inc, Roche Laboratories Inc, Sandoz, Servier.
Jonathan W Friedberg, MD, MMSc
Associate Professor of Medicine and Hematology
Chief, Hematology/Oncology Division
James P Wilmot Cancer Center
University of Rochester
Rochester, New York
Advisory Committee: Cephalon Inc, Genentech BioOncology; Consulting Agreement: Mundipharma International Limited; Data and Safety Monitoring Board: Lilly USA LLC; Paid Research: Millennium — The Takeda Oncology Company, Onyx Pharmaceuticals Inc.
Thomas M Habermann
Professor, Mayo Clinic College of Medicine
No real or apparent conflicts of interest to disclose.
Steven M Horwitz, MD
Lymphoma Service, Division of Hematologic Oncology
Memorial Sloan-Kettering Cancer Center
New York, New York
Consulting Agreements: Allos Therapeutics, Celgene Corporation, Millennium — The Takeda Oncology Company; Paid Research: Allos Therapeutics, Genzyme Corporation.
Brad S Kahl, MD
Director, Lymphoma Service
University of Wisconsin School of Medicine and Public Health
Associate Director for Clinical Research
UW Carbone Cancer Center
Advisory Committee: Celgene Corporation, Cephalon Inc, Genentech BioOncology; Consulting Agreements: Celgene Corporation, Roche Laboratories Inc.
John P Leonard, MD
Richard T Silver Distinguished Professor of Hematology and Medical Oncology
Professor of Medicine, Weill Cornell Medical College
New York, New York
Consulting Agreements: Biogen Idec, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, EMD Serono Inc, Genentech BioOncology, GlaxoSmithKline, Millennium — The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi.
Lauren C Pinter-Brown, MD
Director, UCLA Lymphoma Program
Clinical Professor of Medicine
Geffen School of Medicine at UCLA
Los Angeles, California
Advisory Committee: Allos Therapeutics, Celgene Corporation, Genentech BioOncology, Millennium — The Takeda Oncology Company; Consulting Agreement: Allos Therapeutics; Speakers Bureau: Genentech BioOncology.
Sonali M Smith, MD
Section of Hematology/Oncology
Director, Lymphoma Program
The University of Chicago
Advisory Committee: Allos Therapeutics, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Genentech BioOncology, GlaxoSmithKline, Pfizer Inc, Spectrum Pharmaceuticals Inc; Consulting Agreements: Allos Therapeutics, Celgene Corporation, Cephalon Inc, Genentech BioOncology, GlaxoSmithKline; Speakers Bureau: Biogen Idec, Celgene Corporation, Genentech BioOncology.
EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Millennium — The Takeda Oncology Company, Mundipharma International Limited, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi and Seattle Genetics.
RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This program is supported by educational grants from Celgene Corporation, Genentech BioOncology/Biogen Idec and Millennium — The Takeda Oncology Company.
An Internet connection that is at least 28.8 Kbps
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
Macromedia Flash plug-in 6.0 or greater
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio
Last review date: May 2011
Expiration date: May 2012